James River Group Holdings (JRVR) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
21 Aug, 2026Executive summary
Net income available to common shareholders rose 59% year-over-year to $4.4 million for Q2 2026, with adjusted net operating income at $10.0 million compared to $11.7 million in Q2 2025.
Profitability remains a primary focus, with a 92.8% combined ratio in the E&S segment, reflecting improved underwriting discipline and operational efficiencies.
Deliberate downsizing in the Specialty Admitted segment and expense reductions have led to lower gross written premium but improved efficiency.
The company continues to prioritize underwriting discipline, targeting profitable growth in small and medium enterprise E&S markets.
Technology upgrades and leadership changes have contributed to operational improvements.
Financial highlights
Gross written premium fell 29% year-over-year to $268.9 million, driven by a 17% decline in E&S and a 76% drop in Specialty Admitted Insurance.
Net income of $4.4 million compared to $2.8 million in Q2 2025, a 59% increase.
Group combined ratio was 100.2% for Q2 2026; E&S combined ratio was 92.8%.
Tangible common equity per share was $9.01 at quarter-end.
Net investment income was $20.3 million, stable year-over-year.
Outlook and guidance
Management remains focused on disciplined risk selection, expense management, and operating efficiency, targeting growth in core casualty and specialty divisions.
Competitive market conditions and selective underwriting expected to continue impacting premium volumes.
Technology adoption and operational improvements expected to drive future efficiency and profitability.
Premium retention increased to 55% from 47% year-over-year, reflecting a strategic shift away from fronting business in Specialty Admitted Insurance.
Positive rate opportunities persist in select specialty lines and excess casualty.
Latest events from James River Group Holdings
- Net loss of $10.9M driven by E&S reinsurance charge; E&S segment led growth amid lower premiums.JRVR
Q1 2026 - 2025 marked a sharp turnaround to profitability, capital growth, and E&S-driven operational gains.JRVR
Q4 2025 - Over 21 million common shares registered for resale by major investors, with no proceeds to the company.JRVR
Registration Filing - Annual Meeting to vote on directors, auditor, compensation, and incentive plan amendments.JRVR
Proxy Filing - Proxy covers director elections, auditor re-appointment, compensation, and plan amendments.JRVR
Proxy Filing - Earnings rose on investment gains and strategic actions, but reserve and legal risks persist.JRVR
Q2 2024 - Q3 net loss of $40.7M driven by reserve charges, with E&S premium growth and strategic actions.JRVR
Q3 2024 - Q1 net income dropped to $9M as E&S pricing rose and Specialty Admitted premiums declined.JRVR
Q1 2025 - Q4 2024 net loss of $92.7M; E&S premiums top $1B; 2025 outlook positive.JRVR
Q4 2024